NASDAQ:TCRX TScan Therapeutics - TCRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.56 -0.11 (-4.12%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.54▼$2.7350-Day Range$1.73▼$3.3252-Week Range$1.45▼$4.56Volume9,728 shsAverage Volume49,540 shsMarket Capitalization$62.03 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media TScan Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside485.9% Upside$15.00 Price TargetShort InterestHealthy1.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$4,263 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.13) to ($3.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector297th out of 983 stocksBiological Products, Except Diagnostic Industry49th out of 163 stocks 3.5 Analyst's Opinion Consensus RatingTScan Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, TScan Therapeutics has a forecasted upside of 485.9% from its current price of $2.56.Amount of Analyst CoverageTScan Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.21% of the float of TScan Therapeutics has been sold short.Short Interest Ratio / Days to CoverTScan Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TScan Therapeutics has recently increased by 4.04%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldTScan Therapeutics does not currently pay a dividend.Dividend GrowthTScan Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TCRX. Previous Next 1.2 News and Social Media Coverage News SentimentTScan Therapeutics has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for TScan Therapeutics this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TScan Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,263.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of TScan Therapeutics is held by insiders.Percentage Held by Institutions48.21% of the stock of TScan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for TScan Therapeutics are expected to grow in the coming year, from ($3.13) to ($3.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TScan Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TScan Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTScan Therapeutics has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About TScan Therapeutics (NASDAQ:TCRX) StockTScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Read More Receive TCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TCRX Stock News HeadlinesMarch 15, 2023 | marketwatch.comTScan Therapeutics Shares Rise 8% After First Patient Dosed With TSC-101March 14, 2023 | finance.yahoo.comTScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic MalignanciesMarch 22, 2023 | Upexi, Inc (Ad)The Stock That Is Flying Under Wall St. RadarWith The Founder OF XPO Logistics Leading The Way This Nasdaq Company is Ready and GOING!March 14, 2023 | americanbankingnews.comTScan Therapeutics, Inc. (NASDAQ:TCRX) to Post Q1 2023 Earnings of ($0.70) Per Share, Jefferies Financial Group ForecastsMarch 14, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for TScan Therapeutics, Inc. Decreased by HC Wainwright (NASDAQ:TCRX)March 13, 2023 | finance.yahoo.comTScan Therapeutics to Participate in the Barclays Global Healthcare ConferenceMarch 12, 2023 | americanbankingnews.comTScan Therapeutics' (TCRX) Buy Rating Reiterated at HC WainwrightMarch 10, 2023 | msn.comTScan Therapeutics's Return On Capital Employed InsightsMarch 22, 2023 | Upexi, Inc (Ad)The 1 Stock To Watch In This Market.This NASDAQ Stock Has Been On The Move In 2023 And It Looks Like Its Far From Over!March 10, 2023 | finance.yahoo.comTScan Therapeutics Full Year 2022 Earnings: Misses ExpectationsMarch 9, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and TScan Therapeutics (TCRX)March 9, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on TScan Therapeutics (TCRX)March 8, 2023 | msn.comTScan Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $3.09M misses by $1.01MMarch 8, 2023 | finance.yahoo.comTScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming MilestonesMarch 1, 2023 | finance.yahoo.comTScan Therapeutics to Participate in the Cowen 43rd Annual Health Care ConferenceFebruary 21, 2023 | finance.yahoo.comTScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual ConferenceJanuary 23, 2023 | markets.businessinsider.comTScan Announces FDA Clearance Of 3 INDs For Solid TumorsJanuary 23, 2023 | msn.comTScan stock rises ~15% on FDA nod to start trials of cancer drugsJanuary 23, 2023 | finance.yahoo.comTScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid TumorsJanuary 5, 2023 | finance.yahoo.comTScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent ProgressDecember 12, 2022 | finance.yahoo.comTScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022December 9, 2022 | finance.yahoo.comA number of insiders bought TScan Therapeutics, Inc. (NASDAQ:TCRX) stock last year, which is great news for shareholdersDecember 1, 2022 | finance.yahoo.comTScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston GlobeNovember 22, 2022 | finance.yahoo.comTScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx ConferenceNovember 11, 2022 | finance.yahoo.comTScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual MeetingNovember 9, 2022 | finanznachrichten.deTScan Therapeutics, Inc.: TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 9, 2022 | finance.yahoo.comTScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdateSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TCRX Company Calendar Last Earnings11/10/2021Today3/21/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TCRX CUSIPN/A CIK1783328 Webwww.tscan.com Phone857-399-9500FaxN/AEmployees104Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.00 High Stock Price Forecast$15.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+485.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,220,000.00 Net Margins-489.22% Pretax Margin-489.26% Return on Equity-53.68% Return on Assets-38.66% Debt Debt-to-Equity Ratio0.29 Current Ratio7.17 Quick Ratio7.17 Sales & Book Value Annual Sales$13.53 million Price / Sales4.58 Cash FlowN/A Price / Cash FlowN/A Book Value$4.10 per share Price / Book0.62Miscellaneous Outstanding Shares24,230,000Free Float22,942,000Market Cap$62.03 million OptionableNot Optionable Beta0.44 Key ExecutivesMr. David P. Southwell (Age 62)Pres, CEO & Director Comp: $861.43kMr. Brian Michael Silver J.D. (Age 54)Sr. VP, CFO & Treasurer Comp: $600.13kDr. Gavin MacBeath Ph.D. (Age 53)Chief Scientific & Operations Officer Comp: $571.84kDr. Stephen J. Elledge Ph.D.Co-Founder & Chairman of Scientific Advisory BoardMr. Tomasz Kula Ph.D.Co-Founder & Member of Advisory BoardMr. Ray LockardVP of Technical Operations & QualityMs. Heather SavelleVP of Investor RelationsDr. Zoran Zdraveski J.D. (Age 53)Ph.D., Chief Legal Officer & Company Sec. Ms. Ann HargravesVP of HRDr. William Desmarais M.B.A. (Age 53)Ph.D., Chief Bus. Officer More ExecutivesKey CompetitorsGreenLight BiosciencesNASDAQ:GRNAX4 PharmaceuticalsNASDAQ:XFORBlack Diamond TherapeuticsNASDAQ:BDTXCompugenNASDAQ:CGENOrchard TherapeuticsNASDAQ:ORTXView All CompetitorsInsiders & InstitutionsTang Capital Management LLCSold 43,260 shares on 2/15/2023Ownership: 2.137%Morgan StanleySold 22,395 shares on 2/15/2023Ownership: 0.175%Millennium Management LLCBought 19,244 shares on 2/15/2023Ownership: 0.080%Brian M SilverBought 2,842 shares on 12/27/2022Total: $4,263.00 ($1.50/share)David P SouthwellBought 25,000 shares on 5/18/2022Total: $89,750.00 ($3.59/share)View All Insider TransactionsView All Institutional Transactions TCRX Stock - Frequently Asked Questions Should I buy or sell TScan Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TScan Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TCRX shares. View TCRX analyst ratings or view top-rated stocks. What is TScan Therapeutics' stock price forecast for 2023? 1 Wall Street research analysts have issued 12 month target prices for TScan Therapeutics' shares. Their TCRX share price forecasts range from $15.00 to $15.00. On average, they anticipate the company's share price to reach $15.00 in the next year. This suggests a possible upside of 485.9% from the stock's current price. View analysts price targets for TCRX or view top-rated stocks among Wall Street analysts. How have TCRX shares performed in 2023? TScan Therapeutics' stock was trading at $1.55 at the beginning of the year. Since then, TCRX stock has increased by 65.2% and is now trading at $2.56. View the best growth stocks for 2023 here. When is TScan Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our TCRX earnings forecast. How were TScan Therapeutics' earnings last quarter? TScan Therapeutics, Inc. (NASDAQ:TCRX) posted its earnings results on Wednesday, November, 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by $0.19. The business earned $2.41 million during the quarter. TScan Therapeutics had a negative net margin of 489.22% and a negative trailing twelve-month return on equity of 53.68%. What ETF holds TScan Therapeutics' stock ? BlackRock Future Health ETF holds 1,378 shares of TCRX stock, representing 0.07% of its portfolio. When did TScan Therapeutics IPO? (TCRX) raised $100 million in an initial public offering (IPO) on Friday, July 16th 2021. The company issued 6,250,000 shares at a price of $15.00-$17.00 per share. What is TScan Therapeutics' stock symbol? TScan Therapeutics trades on the NASDAQ under the ticker symbol "TCRX." Who are TScan Therapeutics' major shareholders? TScan Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Tang Capital Management LLC (2.14%), Morgan Stanley (0.18%) and Millennium Management LLC (0.08%). Insiders that own company stock include Brian M Silver, David P Southwell, Gavin Macbeath and Zoran Zdraveski. View institutional ownership trends. How do I buy shares of TScan Therapeutics? Shares of TCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is TScan Therapeutics' stock price today? One share of TCRX stock can currently be purchased for approximately $2.56. How much money does TScan Therapeutics make? TScan Therapeutics (NASDAQ:TCRX) has a market capitalization of $62.03 million and generates $13.53 million in revenue each year. The company earns $-66,220,000.00 in net income (profit) each year or ($2.75) on an earnings per share basis. How many employees does TScan Therapeutics have? The company employs 104 workers across the globe. How can I contact TScan Therapeutics? TScan Therapeutics' mailing address is 830 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.tscan.com. The company can be reached via phone at 857-399-9500 or via email at tscan@argotpartners.com. This page (NASDAQ:TCRX) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.